rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    JANX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Janux Therapeutics: Potential JANX007 Comeback mCRPC And Initial JANX011 Data

      Janux Therapeutics remains a hold, as JANX007 has a potential comeback opportunity, but declining response rates temper enthusiasm. I rate JANX stock as Hold.

      Nov 17Seeking AlphaJANX
      H.C. Wainwright reiterates Janux Therapeutics stock rating at buy
      Nov 12Investing.comJANX
      Why is Janux Therapeutics stock sliding today?
      Nov 12Investing.comJANX
      Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy - Slideshow (NASDAQ:JANX) 2026-11-10

      2026-11-10. The following slide deck was published by Janux Therapeutics, Inc.

      Nov 10Seeking AlphaJANX
      Janux Therapeutics Stock In Focus As Loss Narrows And Phase 1 Data Nears
      Nov 10Yahoo FinanceJANX
      Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
      Nov 9Yahoo FinanceJANX
      Janux Therapeutics (JANX) Earnings Beat Brings Its Pricey Valuation Back Into Focus

      Janux Therapeutics earnings surprise and stock reaction The latest quarter was a catalyst. Janux Therapeutics (JANX) reported a narrower net loss and a smaller loss per share than a year ago, while revenue exceeded analyst expectations. Investors have reacted quickly to the earnings surprise, with a 1 day share price return of 9.78% lifting Janux Therapeutics to US$17.63. A 90 day share price return of 11.23% and a 3 year total shareholder return near 2x suggest longer term momentum, which...

      Nov 7Yahoo FinanceJANX
      Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
      Nov 5Yahoo FinanceJANX
      Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
      Nov 2Yahoo FinanceJANX
      Janux Therapeutics stock may move 6.3% on earnings release
      Oct 30Investing.comJANX
      Janux Therapeutics (JANX) Stock Looks Above Fair Value Based On Sales
      Oct 29Yahoo FinanceJANX
      H.C. Wainwright reiterates Janux stock rating, $45 target
      Oct 19Investing.comJANX
      Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now?
      Oct 13Yahoo FinanceJANX
      Janux Therapeutics (JANX) Stock May Look Overvalued After Its 110% Run
      Oct 10Yahoo FinanceJANX
      Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?

      Janux Therapeutics has recently dosed the first patient in its Phase 1 trial evaluating JANX013 in combination with JANX007 for metastatic castration-resistant prostate cancer, marking a new step in its clinical pipeline. This trial brings fresh attention to Janux Therapeutics’ prostate cancer platform, highlighting how the company is expanding its precision oncology approach into a difficult-to-treat setting. We’ll now examine how progress in this metastatic castration-resistant prostate...

      Sep 29Yahoo FinanceJANX
      Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey

      Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prostate cancer platform. The JANX share price has cooled in the near term, with a 1-month share price return down 9.6% and a 7-day move down 1.75%, even as the 90-day share price return is up 6.36% and the year-to-date share price return stands at 19.41%. Over a...

      Sep 27Yahoo FinanceJANX
      Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed (JANX)
      Sep 18Seeking AlphaJANX
      Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow (NASDAQ:JANX) 2026-09-17
      Sep 17Seeking AlphaJANX
      The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux

      Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.

      Sep 16Yahoo FinanceJANXNVSPFE
      Janux doses first patient in JANX013 prostate cancer trial
      Sep 14Investing.comJANX
      Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

      SAN DIEGO, September 14, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC).

      Sep 14Yahoo FinanceJANX
      Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate
      Sep 14Yahoo FinanceJANX
      Wolfe Research upgrades Janux stock rating on autoimmune data
      Aug 24Investing.comJANX
      This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
      Aug 24BenzingaJANXDRI
      JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

      Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.

      Aug 21Yahoo FinanceJANX

      This is the newest page. Registered accounts read further back.